Eli Lilly
LLY
$2.31 (0.29%)
1D
1W
3M
1Y
5Y
ALL
Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
New York Post • 1 day ago • LLY
FDA approves first medication for obstructive sleep apnea — which also promotes weight lossThe Motley Fool • 1 day ago • LLY
Is Eli Lilly an Undervalued Growth Stock to Buy Now?Investopedia • 3 days ago • LLY
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's ZepboundInvestopedia • 3 days ago • LLY
Lilly Rises on FDA Approval of Weight-Loss Drug-Zepbound for Sleep ApneaSchaeffers Research • 3 days ago • LLY
2 Sleep Apnea Stocks in Focus TodayCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.